Clinical trial · Interventional
SU5416 and Paclitaxel in Treating Patients With Advanced Cancer
Phase I Trial of SU5416 in Combination With Weekly Paclitaxel in Patients With Advanced Malignancies
NCT00006257CI-TRIAL-00003011completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining SU5416 with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining SU5416 and paclitaxel in treating patients who have advanced cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| paclitaxel | Drug | Paclitaxel | ALIAS |
| semaxanib | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically proven advanced malignancy for which no satisfactory treatment exists * Must have tumor accessible by biopsy * Minimum of 1 baseline biopsy required * No brain metastases or primary CNS tumor PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * WHO 0-2 Life expectancy: * At least 3 months Hematopoietic: * Absolute neutrophil count at least 1,500/mm3 * Platelet count at least 100,000/mm3 Hepatic: * SGOT and SGPT less than 2 times upper limit of normal unless due to presence of tumor * Bilirubin normal Renal: * Creatinine no greater than 1.5 mg/dL * Creatinine clearance greater than 60 mL/min Cardiovascular: * No uncompensated coronary artery disease by ECG or physical examination * No myocardial infarction or severe unstable/angina within the past 6 months * No severe peripheral vascular disease associated with diabetes mellitus * No severe deep vein or arterial thrombosis within the past 3 months Pulmonary: * No pulmonary embolism within the past 3 months Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No unstable or severe concurrent medical condition * No active uncontrolled infection * No history of allergic reaction to paclitaxel or Cremophor * No greater than grade 1 peripheral neuropathy PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior SU5416 Chemotherapy: * No prior paclitaxel * Greater than 4 weeks since prior chemotherapy (6 weeks for nitrosourea or mitomycin) and recovered Endocrine therapy: * Not specified Radiotherapy: * Greater than 4 weeks since prior radiotherapy and recovered Surgery: * See Disease Characteristics Other: * Recovered from any prior investigational agents * No other concurrent investigational agents
References
Publications (0)
Data not yet available
No reference posted for this study.